Hypericum extract reverses S-ketamine-induced changes in auditory evoked potentials in humans - Possible implications for the treatment of schizophrenia

Biological Psychiatry

Volumn 59, Issue 5, 2006, Pages 440-445

  Murck, Harald ^a,c   Spitznagel, Heidi ^a   Ploch, Michael ^a   Seibel, Klaus ^b   Schaffler, Klaus ^b  

^a Lichtwer Pharma AG   (Germany)

^b Human Pharmacodynamic Research   (Germany)

^c Amarin Neuroscience Limited   (United Kingdom)

Author keywords

Cognition; Evoked potentials; Glutamate; Hypericum extract; Ketamine; Schizophrenia

Indexed keywords

GLUTAMIC ACID; HYPERICUM PERFORATUM EXTRACT; KETAMINE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG INHIBITION; EVOKED AUDITORY RESPONSE; FEMALE; HEADACHE; HUMAN; HYPERICUM; MALE; MENSTRUAL IRREGULARITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SLEEP DISORDER;

ADULT; COGNITION DISORDERS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EVOKED POTENTIALS, AUDITORY; FEMALE; GLUTAMINE; HUMANS; HYPERICUM; KETAMINE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHYTOTHERAPY; PLANT EXTRACTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33344468239     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2005.07.008     Document Type: Article

References (41)

1. C.M. Adler, A.K. Malhotra, I. Elman, T. Goldberg, M. Egan, D. Pickar Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia Am J Psychiatry 156 1999 1646 1649
2. A.C. Altamura, F. Boin, M. Maes HPA axis and cytokines dysregulation in schizophrenia potential implications for the antipsychotic treatment Eur Neuropsychopharmacol 10 1999 1 4
3. J. Becker, I. Gomes, E.S. Ghisolfi, A. Schuch, F.L. Ramos, J.A. Ehlers Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophrenia Clin Neurophysiol 115 2004 396 401
4. N. Boutros, H. Nasrallah, R. Leighty, M. Torello, P. Tueting, S. Olson Auditory evoked potentials, clinical vs. research applications Psychiatry Res 69 1997 183 195
5. K. Brown, E. Gordon, L. Williams, H. Bahramali, A. Harris, J. Gray Misattribution of sensory input reflected in dysfunctional target nontarget ERPs in schizophrenia Psychol Med 30 2000 1443 1449
6. V. Butterweck, A. Wall, U. Liefländer-Wulf, H. Winterhoff, A. Nahrstedt Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity Pharmacopsychiatry 2 30 Suppl 1997 117 124
7. L.E. Carlson, B.B. Sherwin Relationships among cortisol (CRT), dehydroepiandrosterone-sulfate (DHEAS), and memory in a longitudinal study of healthy elderly men and women Neurobiol Aging 20 1999 315 324
8. A. Carlsson, N. Waters, M.L. Carlsson Neurotransmitter interactions in schizophrenia - Therapeutic implications Eur Arch Psychiatry Clin Neurosci 46 1999 1388 1395
9. L. Cervo, M. Rozio, C.B. Ekalle-Soppo, G. Guiso, P. Morazzoni, S. Caccia Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts Psychopharmacology (Berl) 164 2002 423 428
10. B.A. Clementz, L.D. Blumenfeld Multichannel electroencephalographic assessment of auditory evoked response suppression in schizophrenia Exp Brain Res 139 2001 377 390
11. E.J. Duncan, S.H. Madonick, A. Parwani, B. Angrist, R. Rajan, S. Chakravorty Clinical and sensorimotor gating effects of ketamine in normals Neuropsychopharmacology 25 2001 72 83
12. J.M. Ford, P.M. White, J.G. Csernansky, W.O. Faustman, W.T. Roth, A. Pfefferbaum ERPs in schizophrenia effects of antipsychotic medication Biol Psychiatry 36 1994 153 170
13. S. Frangou, T. Sharma, G. Alarcon, T. Sigmudsson, N. Takei, C. Binnie The Maudsley Family Study, II Endogenous event-related potentials in familial schizophrenia Schizophr Res 23 1997 45 53
14. J.M. Greeson, B. Sanford, D.A. Monti St. John's wort (Hypericum perforatum) a review of the current pharmacological, toxicological, and clinical literature Psychopharmacology (Berl) 153 2001 402 414
15. F. Holsboer The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety Journal of Psychiatric Research 33 1999 181 214
16. K. Jameison, T.G. Dinan Glucocorticoids and cognitive function from physiology to pathophysiology Hum Psychopharmacol 16 2001 293 302
17. D.C. Javitt, M. Jayachandra, R.W. Lindsley, C.M. Specht, C.E. Schroeder Schizophrenia-like deficits in auditory P1 and N1 refractoriness induced by the psychomimetic agent phencyclidine (PCP) Clin Neurophysiol 111 2000 833 836
18. S.T. Kaehler, C. Sinner, S.S. Chatterjee, A. Philippu Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus Neurosci Lett 262 1999 199 202
19. B. Karoumi, A. Laurent, F. Rosenfeld, T. Rochet, A.M. Brunon, J. Dalery Alteration of event related potentials in siblings discordant for schizophrenia Schizophr Res 41 2000 325 334
20. J.H. Krystal, A. Bennett, D. Abi-Saab, A. Belger, L.P. Karper, D.C. D'Souza Dissociation of ketamine effects on rule acquisition and rule implementation possible relevance to NMDA receptor contributions to executive cognitive functions Biol Psychiatry 47 2000 137 143
21. V. Kumar, P.N. Singh, A.V. Muruganandam, S.K. Bhattacharya Effect of Indian Hypericum perforatum Linn on animal models of cognitive dysfunction J Ethnopharmacol 72 2000 119 128
22. A. Laurent, L. Garcia-Larrea, T. d'Amato, J.L. Bosson, M. Saoud, M. Marie-Cardine Auditory event-related potentials and clinical scores in unmedicated schizophrenic patients Psychiatry Res 86 1999 229 238
23. H. Lehfeld, H. Erzigkeit The SKT-a short cognitive performance test for assessing deficits of memory and attention Int Psychogeriatr 1 9 Suppl 1997 115 121
24. G.A. Light, M.A. Geyer, B.A. Clementz, K.S. Cadenhead, D.L. Braff Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications Am J Psychiatry 157 2000 767 771
25. M. Mannel Drug interactions with St John's wort mechanisms and clinical implications Drug Saf 27 2004 773 797
26. W.L. Marsh, J.A. Davies The involvement of sodium and calcium ions in the release of amino acid neurotransmitters from mouse cortical slices elicited by hyperforin Life Sci 71 2002 2645 2655
27. C.R. Maxwell, Y. Liang, B.D. Weightman, S.J. Kanes, T. Abel, R.E. Gur Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential Neuropsychopharmacology 29 2004 739 746
28. H. Murck, M. Uhr, K. Schaffler, K. Seibel Effects of Hypericum extract (LI160) on the change of auditory evoked potentials by cortisol administration Neuropsychobiology 50 2004 128 133
29. J.W. Newcomer, N.B. Farber, V. Jevtovic-Todorovic, G. Selke, A.K. Melson, T. Hershey Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis Neuropsychopharmacology 20 1999 106 118
30. B. Oranje, C.C. Gispen-de Wied, M.N. Verbaten, R.S. Kahn Modulating sensory gating in healthy volunteers the effects of ketamine and haloperidol Biol Psychiatry 52 2002 887 895
31. W.T. Roth, T.B. Horvath, A. Pfefferbaum, B.S. Kopell Event-related potentials in schizophrenics Electroencephalogr Clin Neurophysiol 48 1980 127 139
32. R.M. Sapolsky Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders 57 2000 925 935
33. K. Schaffler, C.H. Wauschkuhn, M. Martinelli, D. Rehn, H. Brunnauer Influences of dimethindene maleate in a new formulation on oculo and psychomotor performance using the oculodynamic test (ODT) in volunteers Agents Actions 41 Spec No: 1994 C136 C137
34. A.M. Shelley, G. Silipo, D.C. Javitt Diminished responsiveness of ERPs in schizophrenic subjects to changes in auditory stimulation parameters implications for theories of cortical dysfunction Schizophr Res 37 1999 65 79
35. M.E. Shenton, S.F. Faux, R.W. McCarley, R. Ballinger, M. Coleman, F.H. Duffy Clinical correlations of auditory P200 topography and left temporo-central deficits in schizophrenia a preliminary study J Psychiatr Res 23 1989 13 34
36. R. Tandon, J.R. DeQuardo, S.F. Taylor, M. McGrath, M. Jibson, A. Eiser, M. Goldman Phasic and enduring negative symptoms in schizophrenia biological markers and relationship to outcome Schizophr Res 45 2000 191 201
37. D. Umbricht, L. Schmid, R. Koller, F.X. Vollenweider, D. Hell, D.C. Javitt Ketamine induced deficits in auditory and visual context-dependent processing in healthy volunteers Implications for models of cognitive deficits in schizophrenia Arch Gen Psychiatry 57 2000 1139 1147
38. B.N. van Berckel, B. Oranje, J.M. van Ree, M.N. Verbaten, R.S. Kahn The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects Psychopharmacology (Berl) 137 1998 271 281
39. D.J. Walder, E.F. Walker, R.J. Lewine Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia Biol Psychiatry 48 2000 1121 1132
40. M.C. Waldo, L.E. Adler, R. Freedman Defects in auditory sensory gating and their apparent compensation in relatives of schizophrenics Schizophr Res 1 1988 19 24
41. M. Wonnemann, A. Singer, W.E. Muller Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's Wort the role of amiloride sensitive sodium conductive pathways Neuropsychopharmacology 23 2000 188 197